Your browser doesn't support javascript.
loading
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2- Advanced Breast Cancer.
Bardia, Aditya; Modi, Shanu; Oliveira, Mafalda; Cortes, Javier; Campone, Mario; Ma, Brigette; Dirix, Luc; Weise, Amy; Hewes, Becker; Diaz-Padilla, Ivan; Han, Yu; Deshpande, Priya; Samant, Tanay S; Lorenc, Karen Rodriguez; He, Wei; Su, Fei; Chavez-MacGregor, Mariana.
Afiliação
  • Bardia A; Departments of Medicine and Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. bardia.aditya@mgh.harvard.edu.
  • Modi S; Breast Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.
  • Oliveira M; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Cortes J; Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain and IOB Institute of Oncology, Quirónsalud Group, Madrid and Barcelona, Spain.
  • Campone M; Department of Oncology, Institute of Cancer Research, Pays de la Loire, France.
  • Ma B; Department of Clinical Oncology, Phase 1 Clinical Trial Center, The Chinese University of Hong Kong, Hong Kong, China.
  • Dirix L; Oncology Centre, Sint Augustinus Hospital, Antwerp, Belgium.
  • Weise A; Department of Hematology & Oncology, Karmanos Cancer Institute, Detroit, Michigan.
  • Hewes B; Medical Department, Repertoire Immune Medicines, Cambridge, Massachusetts.
  • Diaz-Padilla I; Oncology Global Development, Merck Group, Eysins, Switzerland.
  • Han Y; Biostatistics Department, Novartis Pharmaceuticals, East Hanover, New Jersey.
  • Deshpande P; GDO Trial Management - Oncology, Novartis Pharmaceuticals, East Hanover, New Jersey.
  • Samant TS; Pharmacokinetic Sciences, Novartis Pharmaceuticals, East Hanover, New Jersey.
  • Lorenc KR; Global Development, Novartis Pharmaceuticals, East Hanover, New Jersey.
  • He W; Biostatistics Department, Novartis Pharmaceuticals, East Hanover, New Jersey.
  • Su F; Global Development, Novartis Pharmaceuticals, East Hanover, New Jersey.
  • Chavez-MacGregor M; Department of Breast Medical Oncology, Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Clin Cancer Res ; 26(24): 6417-6428, 2020 12 15.
Article em En | MEDLINE | ID: mdl-32998962
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Progesterona / Receptores de Estrogênio / Pós-Menopausa / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Progesterona / Receptores de Estrogênio / Pós-Menopausa / Receptor ErbB-2 Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article